Charles River Laboratories International, Inc. (CRL)
Summary
What Makes Charles River Laboratories (CRL) a Strong Momentum Stock: Buy Now?
Does Charles River Laboratories (CRL) have what it takes to be a top stock pick for momentum investors? Let's find out.
Will Charles River (CRL) Beat Estimates Again in Its Next Earnings Report?
Charles River (CRL) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
LH or CRL: Which Is the Better Value Stock Right Now?
Investors with an interest in Medical Services stocks have likely encountered both Labcorp Holdings (LH) and Charles River Laboratories (CRL). But which of these two companies is the best option for those looking for undervalued stocks?
Charles River Laboratories International, Inc. Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| TJD Thomas John Drogan PR Inc.IPAL SECURITIES Inc. | 6,500 | $1.46M | $1.48M | $15,748.06 | 1.08% |
| CE Curtis Ellergodt Rothschild Investment LLC | 191 | $29,493.01 | $43,420.03 | $13,927.02 | 47.22% |
| ABB Alexander Bjornager Bonde Danske Bank A/S | 100 | $19,948 | $22,733 | $2,785 | 13.96% |
| JD Jim Dushek HARBOUR INVESTMENTS Inc. | 122 | $22,839.15 | $27,729.38 | $4,890.23 | 21.41% |
 John W. Rogers Jr Ariel Investment LLC | 1.44M | $274.06M | $329.67M | $55.61M | 20.29% |
Charles River Laboratories International, Inc. Analysts
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| RG Ricky Goldwasser Morgan Stanley | 1,093.03 | $199,303.24 | $246,347.29 | $47,044.05 | 23.6% |
Charles River Laboratories International, Inc. (CRL) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
Has Charles River Laboratories International, Inc. ever had a stock split?
Charles River Laboratories International, Inc. Profile
| Professional Services Industry | Industrials Sector | James C. Foster CEO | NYSE Exchange | 159864107 CUSIP |
| US Country | 18,700 Employees | - Last Dividend | - Last Split | - IPO Date |
Overview
Charles River Laboratories International, Inc. stands as a pivotal organization within the pharmaceutical industry, providing a comprehensive suite of services encompassing drug discovery, non-clinical development, and safety testing. With a global footprint that extends across the United States, Europe, Canada, the Asia Pacific, and other international markets, the company is recognized for its integrated solutions that support the entire drug development cycle. It operates through three primary segments: Research Models and Services (RMS), Discovery and Safety Assessment (DSA), and Manufacturing Solutions (Manufacturing), each tailored to meet the varied and complex needs of its clients. Founded in 1947 and headquartered in Wilmington, Massachusetts, Charles River Laboratories is dedicated to aiding its clients in the development of novel therapies and medicines through its vast expertise and comprehensive facilities.
Products and Services
Research Models and Services (RMS): This segment is integral to Charles River Laboratories' operations, producing and selling a wide variety of research rodents, including purpose-bred rats and mice. These are essential tools for researchers across the globe, enabling a myriad of scientific investigations and discoveries. Services offered within this segment also include:
- Genetically Engineered Models and Services: Customization and production of genetically modified animals to meet specific research requirements.
- Insourcing Solutions: Provision of skilled personnel and resources to manage and operate clients' laboratory animal facilities.
- Research Animal Diagnostic Services: Comprehensive diagnostic services to ensure the health and genetic integrity of research models.
Discovery and Safety Assessment (DSA): A critical segment that supports early-stage drug discovery and safety assessment. The DSA segment delivers:
- Early and in vivo Discovery Services: Identification and validation of novel targets, chemical compounds, and antibodies, alongside the delivery of preclinical drug and therapeutic candidates ready for safety assessment.
- Safety Assessment Services: Extensive testing services including toxicology, pathology, safety pharmacology, bioanalysis, drug metabolism, and pharmacokinetics to ensure candidate drugs are safe for clinical trials.
Manufacturing Solutions (Manufacturing): This segment provides critical support in the quality control and testing of pharmaceuticals and consumer products. It encompasses:
- In vitro Methods for Quality Control: Testing services for both sterile and non-sterile pharmaceuticals and consumer products, including specialized testing of biologics outsourced by pharmaceutical and biotechnology companies.
- Contract Vivarium Operation Services: Operational support for biopharmaceutical clients’ vivarium facilities, ensuring the maintenance of high-quality standards in animal care and research.
